Germany to start air lifting aid into Gaza
The aid decision was made during an emergency session of senior members of the German cabinet, following intensified tensions with Israel over the deteriorating situation in the Israeli-occupied region.
'We know that this can only be very little help for the people in Gaza, but at least it's a contribution we'd like to make,' Merz told journalists.
He said France and the UK – who form the informal E3 grouping together with Germany – were 'willing' to also take part in the aid operation, which would be carried out in cooperation with Jordan.
Last weekend, the E3 leaders agreed to consider further steps to increase the pressure on Israel to initiate a ceasefire and allow more aid into the Gaza Strip after reports that civilians there were facing mass starvation.
France's President Emmanuel Macron subsequently announced that Paris would unilaterally recognise a Palestinian state in September, though Germany and Britain declined to follow his example.
Merz said that the E3 would start preparing a reconstruction conference for the beleaguered region. That would help 'create leeway for a negotiated solution' to the conflict, Merz added.
Notably, he did not rule out imposing sanctions on Israel, when asked whether the cabinet had considered measures such as halting weapon deliveries to Israel and supporting the suspension of the EU-Israel Association Agreement.
Germany would 'reserve the right' to take such steps, Merz said with regard to the latter.
Berlin had previously refused to support a suspension after an internal EU review found Israel to be in breach of the agreement's human rights commitments.
(jp, aw)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euractiv
39 minutes ago
- Euractiv
European Commission challenges Hungary's 35-year motorway concession
This article is part of our special report EUYou – Europe is you . Read the original. The Commission's position is that the 35-year contract for construction, operation, and maintenance of Hungary's motorway network did not properly transfer operational risk to the concessionaire - a key factor distinguishing concession contracts from public procurement contracts. As a result, the Commission concluded that the contract was incorrectly classified as a concession rather than a public procurement contract, potentially violating principles of equal treatment and transparency. According to Brussels' investigations, the contract modifications also appear to violate EU regulations regarding public procurement contracts. Even if the agreement were to qualify as a concession, the Commission maintains that its duration exceeds the limits permitted by the Concession Directive. Hungary has been given two months to respond and address the identified deficiencies. The motorway concession was conceived by the Orbán government in 2021. The winning consortium comprised several private equity funds, including Themis, Konzum, Opus Bridge, Opus New Way, Cronus, Vesta, and Via Private Equity Funds. These funds are backed by prominent pro-government business figures László Szíjj and Lőrinc Mészáros. The bidding process, overseen by the National Concession Office under Antal Rogán's supervision, initially had three participants. An Austrian construction group was disqualified due to formal errors, leaving just two contenders. The consortium linked to government-affiliated oligarchs predictably won, with contracts signed after the 2022 elections. Under the arrangement, the consortium pays an annual concession fee of several hundred million forints to the state, while receiving access to the annual motorway maintenance budget, which can reach HUF 200-300 billion. Since 2023, MKIF Magyar Koncessziós Infrastruktúra Fejlesztő Zrt. has been managing motorway maintenance, replacing the state-owned ÁAK. The concession has also limited competition in road construction tenders, as MKIF can award contracts to its own companies without competitive bidding. While the government justified the 35-year concession by citing the ability to secure financing for new motorway sections without increasing state debt, no new construction has begun, and planned projects have been cancelled. The European Commission's assessment suggests the concession procedure was irregular, potentially rendering the current contract invalid. While the contract could be modified through dialogue, the Commission may refer the matter to the European Court of Justice if the government proves unwilling to cooperate.
Euractiv
an hour ago
- Euractiv
European wine and spirits not exempt from 15% US tariff
The US will go ahead with a 15% blanket tariff on European wine and spirits from 1 August, despite the appeals from the European Commission and key producing countries to spare the sector. The Commission's trade spokesperson, Olof Gill, confirmed on Thursday that alcoholic beverages are not expected to be excluded from the sweeping measures, which cover nearly all EU imports. "That sector, as with all other economic sectors, will be captured by the 15% ceiling," Gill said, adding that despite the introduction of tariffs, negotiations for more carve-outs will continue. "The Commission remains determined to achieve and secure the maximum number of carve-outs, including for traditional EU products such as wine and spirits," he added. Traditionally, spirits have been traded under a zero-tariff regime since the US and the EU reached an agreement in 1997. While they currently face a 10% US tariff, this will rise to 15% from tomorrow. As for wine – a struggling sector due to a slump in global consumption – the impact of trade tensions since Donald Trump took office is already being felt on both sides of the Atlantic. "In May alone, the sharp decline in EU wine imports drained $479 million from US businesses across the distribution, retail, and hospitality sectors," said Ben Aneff, president of the US Wine Trade Alliance (USWTA). Aneff said US wine exports are down 41% compared to last year. "[This is] an alarming signal of disruption on both sides of the trade equation," he added. Alcoholic beverages are a key EU export to the US, totalling €9 billion, according to Eurostat. In France – the EU's largest exporter of alcoholic drinks – the government had expected spirits to be exempted from the 15% tariff, but not wine. Trade Minister Laurent Saint-Martin said on Monday that Paris would continue pushing to exempt those sectors because "the last word hasn't been said." (adm, aw)
Euractiv
an hour ago
- Euractiv
Irish pharma still risks wildcard Section 232 tariffs, despite Trump's trade agreement
Dublin - Ireland's multibillion-euro pharmaceutical industry is still in a precarious position despite this week's US-EU trade deal. The Trump administration's new 15% tariffs haven't settled market nerves, with a sweeping Section 232 national security investigation in play, and official assurances viewed cautiously. Under this week's US-EU trade framework, a 15 per cent tariff will apply to a wide range of European goods entering the US. While both US and EU officials say most pharmaceuticals will attract the 15% tariff, this remains to be seen pending the outcome of the ongoing Section 232 inquiry, which could trigger even steeper duties. With over €58bn of Ireland's €72.6bn in US exports last year stemming from pharmaceuticals, the risk is significant. The industry underpins nearly 50,000 jobs and is central to Ireland's foreign direct investment model. Speaking after the framework was unveiled, Tánaiste Simon Harris said: 'Whilst the agreement between the EU and the US is welcome, we know that the imposition of any tariffs will have implications and that now is the time to intensify efforts to find and secure more markets for Irish businesses and Irish jobs.' Despite assurances from Brussels, uncertainty prevails in Dublin. One senior cabinet minister, speaking on condition of anonymity, told the Irish Independent: 'We're still in the dark about elements of it… Pharma and semiconductors is where a lot of this will rest and there's still an open question about where they'll end up.' Danny McCoy, CEO of Irish business group Ibec, said the trade agreement 'brings an end to a significant amount of uncertainty for some businesses. However, a 15% tariff still represents a substantial burden for many industries.' He added: 'Pharmaceuticals and semiconductors, which equate to 75% of Ireland-US trade, are, we understand, included in the 15% deal. However, there is still a question around the stability of that rate over both the short and long-term in the face of ongoing Section 232 investigations.' 'Tax scam' rhetoric remains While the European Commission insists pharmaceuticals will not face tariffs above the 15 per cent threshold, citing a 'very clear political commitment' from President Trump, the White House has continued to signal its intent to reconfigure pharmaceutical supply chains. A significant part of this uncertainty stems from previous comments by Commerce Secretary Howard Lutnick, who notoriously described Ireland as his favourite 'tax scam', indicating political appetite for deep sector-specific trade actions. With Ireland still potentially in Trump and Lutnick's sights, Ireland's pharma business group, the IPHA, declined to comment on the trade deal and 15% tariff rate. However, it's understood that the IPHA are aligned with the EFPIA, the European Federation of Pharmaceutical Industries and Associations , which represents the interests of companies such as Pfizer, Roche, and Sanofi. EFPIA has warned against US trade measures, saying, 'Tariffs on medicines are a blunt instrument that will disrupt supply chains, impact on investment in research and development, and ultimately harm patient access to medicines on both sides of the Atlantic.' 'If the intent is to secure pharmaceutical investment in research, development and manufacturing, rebalance trade and ensure a fairer distribution of how global pharmaceutical innovation is financed, then there are more effective means than tariffs that would help, rather than hinder, global advances in patient care and economic growth.' The Section 232 wildcard Since returning to the White House, President Trump has launched 13 Section 232 national security investigations. Four have resulted in tariffs - including steel, aluminium, autos, and most recently copper. A decision on pharmaceuticals is required by late December 2025, within the statutory 270-day window from the investigation's launch in April. However, it is thought likely that the investigation team will report within the next three weeks. A White House official told Euractiv on 28 July: 'When the pharma Section 232 tariffs take effect, the EU will only be subject to 15%.' The following day, the administration published a fact sheet stating: 'As part of President Trump's strategy to establish balanced trade, the European Union will pay the United States a tariff rate of 15%, including on autos and auto parts, pharmaceuticals, and semiconductors.' It's been a long week, and the legal ground remains unsettled. Tariff 'stacking' risk Law firm Covington has warned: 'While initial guidance from the Trump administration provided that Section 232 tariffs would not apply simultaneously (or 'stack') on top of certain other types of tariffs … recent changes to these rules have rendered the stacking question more complex.' 'As additional Section 232 tariffs are announced, further changes to the applicable tariff stacking rules are likely.' President Trump's prior use of Section 232 saw duties of 25 per cent on steel and 10 per cent on aluminium, later raised to 50 per cent. In April, he reiterated his intent to target offshore pharmaceutical production, stating: 'We don't make our own drugs […] anymore. The drug companies are in Ireland, in lots of other places – China – and all I have to do is impose a tariff. The more, the faster they move here.' As with Secretary Lutnick's 'tax scam' remarks, there is no indication that President Trump has softened his stance in any way. The EU trade deal requires $600 billion in investments from Europe, over President Trump's term, part of which will be from the pharmaceutical sector. The White House keeps a public list of inward investment 'wins', and the clock is ticking for pharma to reshore. Trade impact and economic risks The US, which imports over 70 per cent of its essential medicines, could face severe domestic consequences. Generics and hospital injectables - accounting for 90 per cent of prescriptions - are particularly exposed. Medicines for Europe, which represents generic drugmakers, warned that tariffs 'would likely exacerbate the existing shortages in the U.S. and would most likely contribute to a huge wave of additional shortages, including for most products in the essential medicines list.' Reuters reports that analysts at ING estimate that a 15 per cent tariff on pharmaceuticals could slash Irish pharma exports to the US by €8.7bn annually, assuming standard price elasticity and no rapid substitution. EU-wide losses could range from €18bn to €22bn, depending on the final scope and duration of tariffs and other trade measures. Analysts estimate that a 15 per cent tariff could increase US drug prices by 5 - 10 per cent, adding up to $30bn annually to healthcare costs - particularly burdening hospitals and lower-income patients. Increasing healthcare costs ahead of mid-term elections and pushing inflation still higher is a high-risk strategy for the White House. Market response Despite the looming threat, equity markets have responded with cautious optimism. Following the deal's announcement, investors seem to believe that mitigation strategies may buffer the blow. Companies are already anticipating the changes. Sanofi recently sold a New Jersey facility to Thermo Fisher to maintain domestic production. Roche is increasing US inventories, while others are locking in new contract manufacturing agreements. The road ahead In Ireland, the government is convening a national Trade Forum tomorrow, Friday, to assess the fallout. Tánaiste Harris described it as '... a timely opportunity to share and gain insights on what this deal will mean for the future of Irish businesses, jobs, and the economy.' Irish industry leaders continue to call for restraint and clarity, warning that missteps in the coming months could have long-term implications not just for European drug exports, but for American patients and hospitals as well. By Brian Maguire
